heart failure
Conditions
Interventions
Administration of febuxostat 20 mg and inosine 500 mg twice a day for 14 days
Sponsors
Tsukuba International Clinical Pharmacology Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with 20 to 80 years of age 2. Patients with mild or moderate heart failure 3. Those who have the capacity to consent and consented with free will, after sufficient explanation of the purpose and contents of this study, to participate in the study with written document. 4. Patients whose BNP measured within 2 months before the start of the drug administration is higher than the normal range.
Exclusion criteria
Exclusion criteria: 1. Subject who has or had hypersensitivity, idiosyncracy (allergy) to drug. 2. Subjects taking azathioprine or mercaptopurine 3. Subject who has or had renal function disorder. 4. Subject with a history of gout, hyperuricemia or urolithiasis. 5. Patients who changed therapeutic drugs and treatment methods within 1 month before administration of test drugs 6. Subject who was judged not to be appropriate by the principal investigator or sub investigators by other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference of serum BNP between before and after the treatment | — |
Countries
Japan
Contacts
Public ContactMasanori Suzuki
Tsukuba International Clinical Pharmacology Clinic Division for Volunteers
Outcome results
None listed